Exelixis Inc. reported total revenues of $597.8 million for the third quarter ended September 30, 2025, up from $539.5 million in the same period in 2024. Net product revenues for the quarter were $542.9 million, compared to $478.1 million in the prior year period, primarily due to increased sales volume. For fiscal year 2025, Exelixis updated its financial guidance, projecting total revenues between $2.3 billion and $2.35 billion and net product revenues of $2.1 billion to $2.15 billion. Research and development expenses are expected to be $850 million to $900 million, while selling, general and administrative expenses are projected at $500 million to $525 million. Cost of goods sold is estimated at approximately 4% of net product revenues. The company also reported progress in zanzalintinib pivotal trials and phase 1 clinical studies from its early-stage pipeline.